Informationen: Dieses ist nicht die aktuellste Version des Datenmodells. Eine Versionsübersicht finden Sie links unter Versionen. Die aktuellste Version finden Sie hier.
Informationen:
Fehler:
ID
34574
Beschreibung
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02454179
Link
https://clinicaltrials.gov/show/NCT02454179
Stichworte
Versionen (2)
- 19.01.19 19.01.19 -
- 28.05.21 28.05.21 -
Rechteinhaber
see on clinicaltrials.gov
Hochgeladen am
19. Januar 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Squamous Cell Carcinoma of the Head and Neck NCT02454179
Eligibility Squamous Cell Carcinoma of the Head and Neck NCT02454179
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Squamous Cell Carcinoma of the Head and Neck NCT02454179
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
ID.1
Item
men and women ≥ 18 years of age
boolean
ID.2
Item
histologically or cytologically confirmed recurrent, metastatic or unresectable hnscc of the oral cavity, oropharynx, hypopharynx, and larynx that that has either progressed during or after platinum-based chemotherapy administered for metastatic disease or has recurred during or within 6 months after the completion of platinum-based neoadjuvant or adjuvant therapy
boolean
ID.3
Item
presence of radiographically measurable disease as defined by recist 1.1
boolean
ID.4
Item
ecog performance status of 0 or 1
boolean
ID.5
Item
prior malignancy (other than hnscc), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to < 2 years
boolean
ID.6
Item
known central nervous system metastases and/or carcinomatous meningitis
boolean
ID.7
Item
a life-threatening illness, medical condition (including psychiatric conditions) or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety
boolean
ID.8
Item
significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of starting study drug
boolean